

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

PRELIMINARY RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2018

This announcement is made pursuant to Rule 13.09 (2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined by the provisions of Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571) of the Laws of Hong Kong by Livzon Pharmaceutical Group Inc. 麗珠醫藥集團股份有限公司 (the "Company", together with its subsidiaries, the "Group").*

The Company and all members of the board of directors guarantee that the information stated in this announcement is true, accurate and complete and does not contain any false representation, misleading statement or material omission.

Important: The financial data for the six months ended 30 June 2018 set out in this announcement represents figures of preliminary estimations only and has not been audited by an auditing firm. As a result, differences may be found between the data below and the definitive financial data disclosed in the 2018 Interim Report. Investors are advised to be cautious about investment risks involved.

I. PRELIMINARY RESULTS FOR THE PERIOD

1. Period for the preliminary estimated results: 1 January 2018 to 30 June 2018
2. Preliminary estimated operating results: Increase over the corresponding period last year

Item	Current reporting period	Corresponding period last year
Net profit attributable to the shareholders of the listed company	Increased by approximately 20% - 30% as compared to the corresponding period last year	Profit: RMB504.0025 million
	Profit: approximately RMB604.8030 million - RMB655.2033 million	
Net profit attributable to the shareholders of the listed company after deducting the extraordinary gain or loss	Increased by approximately 20% - 30% as compared to the corresponding period last year	Profit: RMB455.2675 million
	Profit: approximately RMB546.3210 million – RMB591.8477 million	
Basic earnings per share (RMB/share)	Profit: approximately RMB0.84 - RMB0.92 per share	Profit: RMB0.70 per share

Note: In July 2017 and June 2018, as a result of the implementation of conversion of capital reserve by the Company, basic earnings per share for the first half year of 2017 has been adjusted based on the latest information of share capital in accordance with the requirement of relevant accounting standards.

II. AUDIT STATUS OF THE PRELIMINARY ESTIMATED RESULTS

The preliminary estimated results have not been audited by certified public accountants.

III. EXPLANATION FOR THE CHANGES IN RESULTS

The results of the Company for the six months ended 30 June 2018 have improved as compared to the corresponding period last year, which is mainly attributable to:

The revenue of drug preparation business segment remained stable year-on-year and that of bulk medicine and diagnostic reagent business segments maintained a steady growth. The further optimization of capital management and the increase in the interest income have led to a continuous steady growth in both operating revenue and profit of the Company in the first half of 2018.

IV. OTHER RELEVANT INFORMATION

1. Figures related to these preliminary estimated results are arrived based on the estimated calculation of the Company, and have not been audited by an auditing firm;
2. Detailed financial information will be disclosed in the 2018 Interim Report of the Company. Potential investors are advised to pay attention to the risks associated with the investment.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc.*
Yang Liang
Company Secretary

Zhuhai, China
12 July 2018

As at the date of this announcement, the Executive Directors of the Company are Mr. Tao Desheng (Vice Chairman and President), Mr. Fu Daotian (Vice President) and Mr. Xu Guoxiang (Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman) and Mr. Qiu Qingfeng; and the Independent Non-Executive Directors of the Company are Mr. Xu Yanjun, Mr. Guo Guoqing, Mr. Wang Xiaojun, Mr. Zheng Zhihua and Mr. Xie Yun.

** For identification purpose only*